Mana.bio Advances AI-Based Lipid Nanoparticle (LNP) Platform to Accelerate "Programmable Drug Delivery" for RNA and Gene Therapies
Mana.bio's integrated experimental and machine learning platform enables the discovery of smarter, faster, more precise delivery formulations to unlock the field of nucleic acid-based and genetic medicines.
- Mana.bio's integrated experimental and machine learning platform enables the discovery of smarter, faster, more precise delivery formulations to unlock the field of nucleic acid-based and genetic medicines.
- We are encouraged by our platform's early in vivo success and for its potential to deliver breakthrough therapies for a broad range of diseases."
- RNA-based therapies and genetic medicines offer immense potential to transform approaches to vaccines, gene editing, gene therapy and more.
- The limitations on delivery methods have severely restricted the full therapeutic promise of RNA, CRISPR and gene therapies.